1. Search Result
Search Result
Results for "

cea positive cancer

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Fluorescent Dyes

2

Inhibitory Antibodies

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D2171

    Fluorescent Dye Others
    AF488 DBCO is a fluorescent dye and also a click chemistry reagent that can label azide-containing biomolecules. AF488 DBCO mediates the coupling reaction with azide-modified 2'-OMe RNA oligonucleotides. DBCO is a bioorthogonal partner of azides and enables covalent coupling without copper (Ex/Em = 470/520 nm) .
    AF488 DBCO
  • HY-178238

    ADC Payload Topoisomerase Cancer
    LD2-3 is a cytotoxic compound derived from Exatecan (HY-13631), designed to be conjugated with anti-FGFR2b or anti-CEA antibodies to form intact antibody-drug conjugate (ADC) molecules. LD2-3 exhibits a remarkable bystander killing effect: it not only effectively kills FGFR2b-positive tumor cells, but also eliminates surrounding FGFR2b-negative cells in co-culture and mixed tumor xenograft models, thereby inducing complete tumor regression. LD2-3 can be used for anti-tumor research in relevant fields such as gastric cancer and lung cancer .
    LD2-3
  • HY-117361

    Nucleoside Antimetabolite/Analog Cancer
    LY207702 is a difluorinated purine nucleoside with antitumor activity and cardiotoxicity. LY207702 is cytotoxic to CEA-positive LS174T cells (IC50=0.302 μg/mL). LY207702 can be used in the study of colon cancer .
    LY207702
  • HY-P992339

    Radionuclide-Drug Conjugates (RDCs) Cancer
    cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies .
    cT84.66
  • HY-P992459

    ADC Antibody Transmembrane Glycoprotein Cancer
    SGM-101 Antibody is a chimeric monoclonal antibody targeting carcinoembryonic antigen (CEA). SGM-101 Antibody can serve as a tumor-specific fluorescent imaging probe after being covalently conjugated with the near-infrared fluorescent dye BM104 . SGM-101 Antibody accumulates in CEA-positive tumor tissues via antigen-antibody specific binding, and emits near-infrared fluorescence to enable imaging of tumor lesions. SGM-101 Antibody can be used in research related to gastric cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, peritoneal carcinomatosis, and liver metastases .
    SGM-101 Antibody

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: